home > news > 2008 > march > world class speakers confirmed for simcyp seminar days
World class speakers confirmed for Simcyp Seminar days
Date: 28 Mar 2008
Simcyp is pleased to announce the programme of confirmed speakers for the forthcoming seminar day - 'Optimizing the use and intepretation of in vitro ADME studies'. This one-day event in San Francisco coincides with our hands-on workshops on the concepts and applications of population-based in vitro-in vivo extrapolation (IVIVE) of ADME properties. We welcome registrations from workshop attendees or delegates who wish to attend the seminar day only.
Simcyp-sponsored seminar days provide an excellent opportunity for informal discussion with invited experts in the field.
Confirmed speakers for the San Francisco seminar on 5th November include:
Leslie Z. Benet - Professor of Biopharmaceutical Sciences UCSF, San Francisco, CA, USA 'In vitro results and BDDCS in predicting transporter effects on drug absorption, disposition and DDIs of NMEs'
Volker Fischer - Senior Director DMPK and Bioanalysis, Abbott, IL, USA 'PBPK vs. Allometry: Case examples for predicting human PK during compound selection and early development'
Andrew Parkinson - Founder & CEO XenoTech, Lenexa, KS, USA 'Induction of drug-metabolizing enzymes: In vitro studies, IVIVE and the emerging role of xenosensors in endobiotic homeostasis'
Carl Peck- Chairman and Founder, NDA Partners LLC. Adjunct Professor, UCSF, Center for Drug Development Science/UCSF, UC-Washington, Washington, DC
Ravi Rahavendran - Associate Director, Pharmacokinetics, Dynamics and Metabolism Department, Pfizer Global R&D. La Jolla, CA, USA 'Simcyp as a risk prediction and assessment tool in drug discovery and development - selected case examples'
Malcolm Rowland - Professor Emeritus, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, UK 'Why are we doing patient population pharmacokinetic studies?'
Magang Shou - Director of Pharmacokinetics and Drug Metabolism, Amgen Inc. Thousand Oaks, CA, USA 'Kinetic approaches and correlation analyses for prediction of clinical drug interactions from in vitro CYP3A4 induction data'
Donald Stanski - MD, Global Head Modelling and Simulation, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA 'Creating an integerated modelling and simulation department: lessons learned'
Geoff Tucker - Professor, Academic Unit of Clinical Pharmacology, University of Sheffield, UK “All models are wrong - but some are useful”
John A. Wagner - MD, PhD Executive Director, Clinical Pharmacology, Merck Research Laboratories, Acting Scientific Discipline Integrator, Merck SIMS Rahway, NJ, USA 'Strategically Integrated Modelling and Simulation (SIMS) in early and late drug development'
Diane Wang - Director, Clinical Pharmacology, Oncology, Pfizer Global R&D, La Jolla, CA, USA 'Application of modelling and simulation in pre-clinical and clinical drug development - case examples'
Walter Woltosz - Chairman & CEO, Simulations Plus, Inc., CA, USA 'Overcoming skepticism in widespread use of M&S in drug discovery and development - 11 years of experience in Simulation Plus'